Royalty Pharma (RPRX) EBT Margin (2019 - 2026)
Royalty Pharma (RPRX) posted EBT Margin of 74.26% for Q1 2026, up 29.77% sequentially from 57.22% in Q4 2025, and down 219.0% YoY from 62.4% in Q1 2025.
Royalty Pharma (RPRX) EBT Margin (2019 - 2026) Analysis & Trends
Royalty Pharma has reported EBT Margin for 8 years, with the latest figure at 74.26% in Q1 2026.
- Quarterly EBT Margin fell 219.0% year-over-year to 74.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55.69% (down 2248.0% YoY) and the FY2025 annual result came in at 55.68%, down 311.0% from the prior year.
- EBT Margin grew to 74.26% in Q1 2026 per RPRX's latest filing, from 57.22% in the prior quarter.
- Over five years, EBT Margin peaked at 142.8% in Q3 2024 and troughed at 107.83% in Q4 2022.
- A 5-year average of 50.53% and a median of 57.22% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin tumbled 11715 bps in 2022, then jumped 22821 bps in 2023.
- Over 5 years, EBT Margin stood at 107.83% in 2022, then soared by 212 bps to 120.39% in 2023, then tumbled by 53 bps to 56.32% in 2024, then increased by 2 bps to 57.22% in 2025, then gained by 30 bps to 74.26% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 74.26%, 57.22%, and 72.91% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -20,427.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.09% |
| Mar 31, 2026 | 74.26% |
| Dec 31, 2025 | 57.22% |
| Sep 30, 2025 | 72.91% |
| Jun 30, 2025 | 15.66% |
| Mar 31, 2025 | 76.45% |
| Dec 31, 2024 | 56.32% |
| Sep 30, 2024 | 142.80% |
| Jun 30, 2024 | 36.18% |
| Mar 31, 2024 | -0.75% |
| Dec 31, 2023 | 120.39% |
| Sep 30, 2023 | 22.76% |
| Jun 30, 2023 | 65.28% |
| Mar 31, 2023 | 74.43% |
| Dec 31, 2022 | -107.83% |
| Sep 30, 2022 | 38.44% |
| Jun 30, 2022 | 91.72% |
| Mar 31, 2022 | 22.79% |
| Dec 31, 2021 | 9.32% |
| Sep 30, 2021 | 37.86% |